Amlodipine Besylate 10 mg Tablets Recalled for Failing Potency Tests
Lupin Pharmaceuticals recalls Amlodipine Besylate 10 mg tablets (Lot A102887) after stability testing revealed the tablets failed potency specifications, containing less active ingredient than labeled. Patients should contact their pharmacist or doctor.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class III recalls are typically rated 1 or 2. This recall involves a potency specification failure with no reported illnesses or injuries. While subpotency could reduce therapeutic efficacy in a cardiovascular medication, the absence of reported harm and the Class III classification support a moderate rather than low severity.
Plain-English summary
Lupin Pharmaceuticals Inc. is recalling approximately 3,096 bottles of Amlodipine Besylate Tablets, USP 10 mg due to subpotency. During a 21-month long-term stability study, testing showed the tablets contained less active ingredient than specified, resulting in an out-of-specification assay result.
Amlodipine Besylate is a prescription medication used to treat high blood pressure and chest pain. When tablets are subpotent, they may not provide the intended therapeutic effect. The affected product has Lot Number A102887 with an expiration date of 6/2023.
The recalled product was distributed directly to three distributors in Tennessee and New Jersey. Product may have been further distributed throughout the United States. Patients currently taking this medication should contact their pharmacist or healthcare provider immediately to discuss their medication and determine if they have received any of the recalled product.
Consumers or healthcare providers who have the recalled product should stop using it and return it to their pharmacy for proper disposal or replacement with product that meets specification.
The recalled product
- Product
- AMLODIPINE BESYLATE (AMLODIPINE BESYLATE)
- Brand
- AMLODIPINE BESYLATE
- Manufacturer
- Lupin Pharmaceuticals Inc.
- Category
- Drug — Prescription Oral
- Affected units
- 3,096
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: A102887
- Exp. 6/2023
UPCs (1)
- 0368180233022
Distribution
Related recalls
Same brand · AMLODIPINE BESYLATE
- ModerateInvaGen Recalls Amlodipine Besylate Tablets Due to Subpotency
FDA (Drugs) · 2018-10-17
- ModerateAscend Amlodipine Besylate Tablets Recalled for Foreign Tablet Presence
FDA (Drugs) · 2017-09-20
- LowLupin Recalls Amlodipine Besylate Tablets Due to CGMP Deviations
FDA (Drugs) · 2016-09-14
- ModerateLupin Recalls Amlodipine Besylate Tablets Due to CGMP Deviations
FDA (Drugs) · 2016-09-14
- LowZydus Recalls Amlodipine Besylate Tablets Due to Discoloration
FDA (Drugs) · 2014-12-03
Same manufacturer · Lupin Pharmaceuticals Inc.
See all →- ModerateLupin Recalls Clobetasol Propionate Cream for Content Uniformity Failures
FDA (Drugs) · 2026-09-02
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighPrednisolone Acetate Ophthalmic Suspension Recalled for Foreign Substance
FDA (Drugs) · 2026-07-08
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- ModerateGanirelix acetate injection recalled after failing an impurity specification
FDA (Drugs) · 2025-12-17
Same hazard · subpotency
See all →- ModerateGood Neighbor Pharmacy Earwax Removal Drug Recalled for Low Potency
FDA (Drugs) · 2026-07-22
- ModerateNystatin Cream Recall Due to Low Potency Test Results
FDA (Drugs) · 2026-07-22
- ModerateFoster & Thrive Carbamide Peroxide 6.5% Recalled for Subpotent Strength
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- ModerateMeijer Earwax Removal Kit Recalled for Subpotent Active Ingredient
FDA (Drugs) · 2026-07-22